宏类维持疗法在支气管切除症患者中的心血管益处和安全性概况
Ran Guo1,2, Dennis Wat3, Steven Ho Man Lam4,5
1Division of Cardiology, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, Shen Zhen, China.
The European respiratory journal
|November 27, 2024
概括
宏类维持疗法 (MMT) 在支气管切除症患者中显著降低了主要心血管不良事件 (MACE). 这种疗法没有增加危险心律失常的风险,提供潜在的心血管益处.
科学领域:
- 肺部病理学 肺部病理学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 支气管切除与心血管事件风险增加有关.
- 宏类维护疗法 (MMT) 减少支气管切除症的恶化.
- 在支气管切除中,MMT对心血管的益处和安全性尚未得到充分证实.
研究的目的:
- 在支气管切除症患者中评估MMT对心血管的益处.
- 评估MMT与心律失常有关的安全性.
主要方法:
- 在香港 (2001-2018) 进行了全境的队列研究.
- 倾向性得分匹配用于比较MMT接收者和非接收者.
- 主要结局:主要不良心血管事件 (MACE);安全结局:心室节律失常/心脏突然死亡.
主要成果:
- MMT与MACE (HR 0.68) 的风险显著降低有关.
- 没有观察到MMT (HR 0.93) 增加心室节律失常或心脏突然死亡的风险.
结论:
- 在支气管切除症患者中,MMT显著降低了MACE风险.
- 在这个人群中,MMT对于严重心律失常相关的不良事件是安全的.
更多相关视频
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179
Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245
Antiasthma Drugs: β2-Adrenoceptor Agonists
233
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
233
Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
Antiasthma Drugs: Methylxanthines
195
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
195
Cystic Fibrosis: Management
142
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
142


